Author: Pham, Phuc Van; Vu, Ngoc Bich
Title: Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations Cord-id: otr94at6 Document date: 2020_8_26
ID: otr94at6
Snippet: Coronavirus disease-2019 (COVID-19) has affected more than 200 countries worldwide. This disease has hugely affected healthcare systems as well as the economy to an extent never seen before. To date, COVID-19 infection has led to about 165000 deaths in 150 countries. At present, there is no specific drug or efficient treatment for this disease. In this analysis based on evidential relationships of the biological characteristics of MSCs, especially umbilical cord (UC)-derived MSCs as well as the
Document: Coronavirus disease-2019 (COVID-19) has affected more than 200 countries worldwide. This disease has hugely affected healthcare systems as well as the economy to an extent never seen before. To date, COVID-19 infection has led to about 165000 deaths in 150 countries. At present, there is no specific drug or efficient treatment for this disease. In this analysis based on evidential relationships of the biological characteristics of MSCs, especially umbilical cord (UC)-derived MSCs as well as the first clinical trial using MSCs for COVID-19 treatment, we discuss the use of UC-MSCs to improve the symptoms of COVID-19 in patients.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and additional therapy: 1, 2
- acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
- acute ards respiratory distress syndrome and adipose tissue bone marrow: 1, 2
- acute ards respiratory distress syndrome and liver dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute ards respiratory distress syndrome and low effect: 1, 2
- acute ards respiratory distress syndrome and low immunogenicity: 1, 2, 3
- acute ards respiratory distress syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute cardiac injury and liver dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute cardiac injury and lung inflammation: 1, 2
- acute cardiac injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- additional therapy and liver dysfunction: 1
- adipose tissue and liver dysfunction: 1
- adipose tissue and low effect: 1
- adipose tissue and low immunogenicity: 1
- adipose tissue and lung inflammation: 1, 2, 3, 4, 5
- adipose tissue and lung inflammation control: 1
- adipose tissue and lung injury: 1, 2, 3, 4, 5, 6, 7
- adipose tissue bone marrow and low immunogenicity: 1
Co phrase search for related documents, hyperlinks ordered by date